Ep196: Otello Stampacchia on Europe's Biotech Crisis

Episode Summary

Executive Summary: Luke Timmerman and OmegaFunds’ Otello Stampacchia argue Europe must urgently fix fragmented capital markets, slow regulation, and weak risk appetite if it wants to remain competitive in biotech. They say Europe’s science is world-class, but policy, financing, and trial-speed bottlenecks push companies, capital, and talent toward the U.S. and China.

Main Topics: Europe’s biotech competitiveness problem (Priority: 5/5): Stampacchia frames European biotech as scientifically strong but structurally weak: innovation is there, but commercialization, scale-up, and public-market support lag badly behind the U.S. Capital-market fragmentation and risk appetite (Priority: 5/5): The discussion centers on Europe’s under-allocation of institutional capital to venture and the lack of a unified, liquid public market for growth companies, which makes scaling harder and often sends listings to the U.S. Regulatory and clinical-trial bottlenecks (Priority: 5/5): They identify fragmented and slow clinical approval, manufacturing certification, and reimbursement frameworks as major barriers that undermine Europe’s speed advantage versus competitors like Australia and China. European Life Sciences Coalition and policy advocacy (Priority: 4/5): Stampacchia explains the coalition’s formation and strategy: mobilize capital, improve public markets, and engage European and national policymakers, regulators, and the EMA with a focused agenda. Geopolitics, U.S. pressure, and China’s challenge (Priority: 5/5): The conversation links biotech policy to broader geopolitical shifts: U.S. pressure to onshore investment and China’s speed/cost advantage are squeezing Europe from both sides. Talent flow, immigration, and entrepreneurial culture (Priority: 4/5): They discuss how U.S. immigration dynamics and Europe’s bureaucracy may shape where scientists and founders choose to build companies, with Europe needing both structural reform and stronger role models. Pricing, access, and the tradeoff in drug policy (Priority: 4/5): The hosts debate whether Europe should pay more for medicines; Stampacchia argues low prices can backfire by driving investment away and ultimately limiting patient access to innovation.

Key Arguments: Europe does not lack scientific talent or savings; it lacks a mechanism to convert them into scalable biotech companies and liquidity. European pension funds allocate about 0.02% to venture versus about 2% in the U.S., showing a massive risk-appetite gap. Europe’s public-growth-company markets are fragmented across venues like AIM, Euronext, Nasdaq OMX Nordics, and Swiss SIX, which weakens liquidity and makes U.S. listings more attractive. Most European biotech firms that go public list outside the EU; the cited pattern was 66 of 67 over roughly six years. Clinical trials and manufacturing certification are too slow in Europe; if trials can start in two months in some jurisdictions versus six in Europe, Europe loses competitive ground. The coalition’s advocacy must be focused, not sprawling: mobilize capital, improve public markets, and push selected regulatory fixes. Low drug prices can create a false sense of victory if they cause investment, jobs, and access to future medicines to move elsewhere. U.S. policy pressure and China’s speed/cost advantages create a two-sided squeeze on Europe’s life-sciences ecosystem. Europe should treat biotech as a strategic industry on par with defense and energy because it supports growth, employment, and public health. A stronger European biotech ecosystem would also help attract talent and keep entrepreneurial role models within Europe.

Data Points: Global share of biotech healthcare VC going to Europe: ~7% - Used to show Europe’s small share of venture financing compared with the U.S. Global share of biotech healthcare VC going to the U.S.: ~63% - Illustrates the U.S. dominance in biotech venture capital. European pension-fund allocation to venture: 0.02% - Stampacchia cites this as evidence of Europe’s extremely low institutional risk appetite. U.S. pension-fund allocation to venture: 2% - Contrasted with Europe to show roughly two orders of magnitude more risk capital in the U.S. European biotech IPOs over roughly six years: 67 companies - A cited sample of European companies going public. European biotech IPOs listing outside the EU: 66 of 67 - Shows Europe’s lack of attractive local public markets for growth companies. Healthcare employment in Europe: ~29 million people - Includes the broader sector, illustrating biotech’s importance within the European economy. Healthcare sector growth rate in Europe: ~7% per year - Presented as a strong-growth sector relative to Europe’s slower overall GDP growth. Typical strong GDP growth in leading European economies: ~1.5% per year - Used as a contrast with healthcare sector growth. Coalition investment coverage: ~1,400 companies over a couple of decades - Stampacchia describes the collective experience of the coalition members. Clinical trial start time comparison: 2 months vs. 6 months - Example used to show how faster jurisdictions can outcompete Europe on trial initiation.

Pivotal Quotes: "we are market actors who are rewarded for market success" — Otello Stampacchia: Explaining why venture investors can identify market failures in Europe more credibly than policymakers alone. "if you can start up a clinical trial in two months versus six months, that makes a big, big difference" — Otello Stampacchia: Describing the importance of regulatory speed for biotech competitiveness. "If we shift from a pricing issue to an access issue for Europe" — Otello Stampacchia: Warning that low prices may lead to reduced availability of innovative medicines in Europe.

Implications: Europe’s biotech future depends on coordinated reform: more venture/pension capital, faster trials, better public markets, and talent-friendly policies. Without it, scientific excellence may keep flowing to the U.S. or China instead of becoming European companies and medicines.